GOSS
Gossamer Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.18
−0.17%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.3x
Market Cap
$85.69M
MomentumView details →
1D Return
−0.17%
YTD Return
−94.32%
RSI (14)
52.3
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.3x
Market Cap
$85.69M
RSI (14)
52.3
MomentumView details →
1D Return
−0.17%
YTD Return
−94.32%
SummaryUpdated Jun 1, 2026
Gossamer Bio, Inc. (NASDAQ:GOSS) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in San Diego, California. The company went public in February 2019 and focuses on discovering, acquiring, developing, and commercializing innovative therapeutics targeting immunology, inflammation, and oncology. Originally incorporated as FSG Bio, Inc., the company changed its name to Gossamer Bio in 2017. Gossamer Bio operates as a development-stage biotechnology company with multiple drug candidates in various phases of clinical trials, positioning itself to address significant unmet medical needs in rare and serious diseases.
Similar companies
Latest newsMore news →
Gossamer Bio, Inc. signed a structured private placement on August 20, 2026, to raise up to $250 million through the sale of pre-funded warrants exercisable for convertible preferred stock and FDA Approval Warrants, with an initial closing expected on August 24, 2026.15d agoGossamer Bio exchanged $181.1 million of its 2027 convertible notes for $65.2 million of new 2030 notes, reducing debt by $115.9 million.23d agoGossamer Bio reported Q2 2026 revenue of $9.2 million and a net income of $16.9 million, with diluted EPS of -$0.08.23d ago